Coloplast reaffirmed its FY 2025 guidance of 8%-9% organic revenue growth and an EBIT margin of approximately 28%. The company anticipates second-half-weighted growth, driven by recovery in ...

Stay up to date on how Coloplast AS ADR (CLPBY:PINX) stock has performed compared to similar stocks in the same industry on a daily, quarterly, and monthly basis.

Terry Smith slammed two of Denmark’s largest life sciences companies — Novo Nordisk A/S and Coloplast A/S — after they weighed on the equity fund run by the man often dubbed ‘Britain’s Warren Buffett.

Coloplast A/S is acquiring Kerecis hf, a closely held Icelandic maker of fish-skin dressings to treat human wounds, for an enterprise value of up to $1.3 billion.

Coloplast remains a leader in intimate healthcare with strong growth, innovation, and dividend support, despite recent weakness. See why CLPBY stock is a buy.

Coloplast's stock is down 25% but still overvalued. Learn about CLPBF stock's intrinsic value, growth stats, and if a 20% dip signals a better entry point.

Coloplast has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up to $1.3 billion, the Danish medical equipment maker ...

Coloplast A/S. Tuesday, 6 May 2025 at 11.00 - 12.00am CEST In connection with the publication of Coloplast’s interim financial results for H1 2024/25, to be released same day around 07.30am CEST ...

Coloplast A/S, the Danish maker of medical products, agreed to pay about $16 million to settle lawsuits over claims it injured women with its vaginal-mesh inserts, three people familiar with the ...

Coloplast's ownership structure favors the holders of A shares (mainly the Louis-Hansen founding family), which holds 44% of the equity but retains 68% of the voting power.

Coloplast delivered Q4 organic growth of 8% and an EBIT margin 1 of 26%, which was negatively impacted by extraordinary costs and currencies. Reported revenue in DKK grew 12% with 3%- pts ...